This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Data Quantifying The Effects Of Opioid Use On Patient Care And Economic Outcomes Presented At Key Medical Meetings

Stocks in this article: PCRX

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data that demonstrate opioid-related adverse drug events (ORADEs) following laparoscopic or open gastrointestinal (GI) surgeries increased total hospitalization costs by up to $12,724 and as much as doubled the length of hospital stay (LOS), depending on the type of surgical procedure performed. These findings were presented today during a poster session at the American Society of Colon and Rectal Surgeons (ASCRS) annual meeting in San Antonio, Texas.

Data from this regional retrospective analysis were drawn from 26 participating member hospitals of VHA Southeast (a regional office of VHA, Inc.), and included patients who underwent select laparoscopic or open GI surgeries and received opioid-based pain management regimens from January 2009 to December 2010. The research was supported by Pacira Pharmaceuticals, Inc.

Compared to patients who did not experience an ORADE:

  • Mean total hospitalization costs increased by $7,949 and $12,724 for patients experiencing an ORADE after a laparoscopic or open GI procedure, respectively.
  • Mean LOS was 1.5-1.9 times and 1.3-2.0 times longer for patients experiencing an ORADE after a laparoscopic or open GI procedure, respectively.

“These types of analyses continue to quantify the significant impact opioids have on our patients and the economics of hospital care in the United States,” said Dave Stack, president and CEO of Pacira Pharmaceuticals. “These data demonstrate that even in laparoscopic procedures, which are less invasive and intended to provide quicker patient recovery, opioid-related adverse events including nausea, vomiting, constipation, urinary retention and respiratory depression can significantly impact patient healing and hospital discharge.”

Additionally, new national data on the impact of ileus following postsurgical opioid use were presented during a poster session held today at the 17th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Washington, D.C. Ileus is a partial or complete blockage of the small and/or large intestine resulting in greatly impaired or lost bowel function. It is a complication significantly associated with abdominal procedures that can be exacerbated by opioid use.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs